Yi-An Chu Sells Shares of Apollomics, Inc. (APLM)

Yi-An Chu sold 500 shares of Apollomics, Inc. on June 15, 2026.

Written by EarningsIQ · Published Jun 17, 2026, 2:01 AM EDT · Updated Jun 17, 2026, 6:01 AM EDT

Key Points

Yi-An Chu sold 500 shares of Apollomics, Inc. on June 15, 2026, with no disclosed transaction value.
Apollomics, Inc. trades at $13.85 with a market cap of approximately $31.8 million and a 52-week range between $3.66 and $42.12.
CITIGROUP INC and UBS GROUP AG have increased their holdings in Apollomics, while Kestra Advisory Services, LLC exited its position.

Yi-An Chu, an insider at Apollomics, Inc. (NasdaqCM: APLM), sold 500 shares of the company on June 15, 2026. Although the transaction didn't have a disclosed value, it reflects a movement in insider holdings at the biotechnology firm.

Other Institutional Activity in Apollomics, Inc.

CITIGROUP INC boosted its holdings by 438 shares, ending with a total of 438 shares worth about $6,811. UBS GROUP AG also increased its stake by 78 shares, bringing its total to 142 shares valued at approximately $2,251. Meanwhile, Kestra Advisory Services, LLC exited its position, reducing its holdings by 4,380 shares.

Apollomics, Inc. Stock Snapshot

Shares of Apollomics, Inc. are trading at $13.85. The company has a market cap of about $31.8 million. Its forward P/E is not meaningful due to a lack of profitability, and it has a beta of 1.526. The stock's 52-week range is between $3.66 and $42.12, with a 50-day moving average of $14.25 and a 200-day moving average of $16.91.

Insider Buying and Selling at Apollomics, Inc.

On June 15, 2026, several insiders made transactions at Apollomics, Inc. Chen Hong-Jung and CEO Chen Hung-Wen each bought 500 and 5,000 shares respectively, with no disclosed price. Conversely, insiders Jan Chen-Huan and Tsai Hsien-Shu sold 500 shares each, also with no price stated. COO Chen Yi-Kuei sold 5,000 shares.

Analysts Set New Price Targets

H.C. Wainwright reiterated its 'buy' rating on Apollomics, Inc. with various target prices, including $2.00 on May 8, 2024, and $17.00 on November 20, 2023. EF Hutton maintained a 'buy' rating with a target of $25.00 on May 25, 2023.

About Apollomics, Inc.

Apollomics, Inc. is a clinical-stage biopharmaceutical company based in Foster City, California. The company focuses on developing oncology therapies that harness the immune system and target specific molecular pathways to treat cancer. Its product lineup includes Vebreltinib, a c-Met inhibitor, and APL-102, a tyrosine kinase inhibitor, among others. Founded in 2015, Apollomics aims to advance cancer treatment through innovative drug development.

Bottom Line

Yi-An Chu's recent share sale at Apollomics, Inc. is part of broader insider activity at the company. Investors often watch these transactions for insights into insider sentiment. It's important to remember that 13F filings and insider transactions are historical and may not reflect current holdings or strategies.